The latest PRISMAP Call 5 was again a success, with 24 proposals submitted! These proposals highlighted a wide range of innovative approaches in radiopharmaceutical development for cancer therapy and imaging, as well as advancements in radioisotope production.

In parallel, under the leadership of Belgium, the Council of the European Union approved a resolution on June 17, 2024, emphasizing Europe’s need to maintain autonomy and leadership in the medical radioisotope field.This is especially important given that production is concentrated in only a few member states, and some isotopes have a very short half-life, posing challenges for availability and transport. The resolution calls for collaboration among the European Commission, Euratom Supply Agency, member states, and industry stakeholders to secure source materials, sustain research, and improve transport logistics. This initiative builds on previous EU strategies, like the 2021 SAMIRA strategy, to strengthen nuclear medicine and support Europe's Beating Cancer Plan.

The Economic and Social Committee's report on “Europe's Beating Cancer Plan” highlights the life-saving impact of nuclear medicine and the need for equal access to cancer treatment across Europe. It stresses the importance of prioritising radionuclide-targeted therapies due to their precision and reduced harm, and calls for investment in workforce education, training, and mobility.

This edition features several exciting events and opportunities for the PRISMAP community. Notably, we will have a PRISMAP session at the Workshop on Radionuclide Production and Medical Application in Oslo (May 12-16, 2025), organised by the Norwegian Nuclear Research Centre. Additionally, the ISOLPHARM group of PRISMAP partner INFN will organize a thematic workshop at the FisMat 2025 conference in Venice (July 7-11, 2025), focusing on the ISOL technique for medical radionuclide production. Mark also your calendars for the International Day of Women in Radiopharmaceutical Sciences webinar on August 18, 2025, celebrating women’s contributions to the field.

We also have a number of upcoming international conferences where PRISMAP will be represented, including ECR 2025 (Vienna), EMIS 2025 (Whistler, BC, Canada) and INPC 2025 (Daejeon, Korea). Further details on participation and submission opportunities are included.

We are very much looking forward to welcoming you in Mol, Belgium for the upcoming Consortium Meeting 8 organised by Lucia Popescu, early April. This consortium meeting will include a public event, "PRISMAP Meets Industry," where we aim to foster further collaboration and engagement with stakeholders in the radiopharmaceutical industry.

Finally, as a last focus of this newsletter, we would like to highlight the Nuclear Medical Applications infrastructures at SCK CEN, which are depicted at the end of the newsletter. These groundbreaking efforts are shaping the future of radiopharmaceuticals in the fight against cancer.

We look forward to continued engagement and collaboration in these exciting initiatives, which are driving the future of radiopharmaceutical research and its application in cancer therapy in Europe and beyond.